Browse > Article

A Case of Pyrazinamide Induced Fulminant Hepatic Failure  

Moon, Dae Sung (Department of Internal Medicine, College of Medicine, Kosin University)
Jang, Tae Won (Department of Internal Medicine, College of Medicine, Kosin University)
Oak, Chul Ho (Department of Internal Medicine, College of Medicine, Kosin University)
Jung, Maan Hong (Department of Internal Medicine, College of Medicine, Kosin University)
Yoo, Chan Hui (Department of Internal Medicine, College of Medicine, Kosin University)
Song, Jun Young (Department of Internal Medicine, College of Medicine, Kosin University)
Kim, Sung Eun (Department of Internal Medicine, College of Medicine, Kosin University)
Kim, Ja Kyung (Department of Internal Medicine, College of Medicine, Kosin University)
Jang, Lee La (Department of Internal Medicine, College of Medicine, Kosin University)
Lee, Eun Young (Department of Internal Medicine, College of Medicine, Kosin University)
Jung, Gyu Sik (Department of Radiology, College of Medicine, Kosin University)
Publication Information
Tuberculosis and Respiratory Diseases / v.63, no.5, 2007 , pp. 435-439 More about this Journal
Abstract
Standard antituberculous therapy, including isoniazid (INH), rifampin, ethambutol, and pyrazinamide (PZA), is widely used to treat active tuberculosis. The most important side effect is hepatotoxicity. In a standard four-drug regimen, PZA was the most common cause of drug-induced hepatitis and was dose-related. The incidence of drug-induced hepatitis is high at doses of 40~70 mg/kg per day but has fallen significantly since the recommended dose was reduced. Liver toxicity induced by PZA is rare at doses of 25 mg/kg per day or less. PZA-induced fulminant hepatic failure is also rare but fatal. We report a case of fulminant hepatic failure caused by a re-challenge of PZA.
Keywords
Drug induced hepatitis; Fulminant hepatic failure; Pyrazinamide;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax 1996;51:111-3   DOI   ScienceOn
2 Schaberg T, Rebhan K, Lode H. Risk factors for side-effect of isoniazide, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30   DOI   ScienceOn
3 Smink F, van Hoek B, Ringers J, van Altena R, Arend SM. Risk factors of acute hepatic failure during antituberculosis treatment: two cases and literature review. Neth J Med 2006;64:377-84
4 Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995;8:1384-8   DOI   ScienceOn
5 Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl 2006;12:1427-30   DOI   ScienceOn
6 McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33. Erratum in: Clin Infect Dis 2006;42:313
7 Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929-32   DOI   ScienceOn
8 Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7   DOI   ScienceOn
9 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62   DOI   ScienceOn
10 Danan G, Pessayre D, Larrey D, Benhamou JP. Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again. Lancet 1981;2:1056-7
11 Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48   DOI   ScienceOn
12 Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associate with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three pubic health tuberculosis clinics. Int J Tuberc Lung Dis 2002;6:995-1000
13 Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:579-85
14 Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985;132:374-8
15 Third East African/British Medical Research Councils Study. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis 1978;118:39-48